Annual Report 2024
Novo Nordisk employees Steve Piaget and Marie Ange Gahozo from our site in Kalundborg, Denmark, overseeing an active construction project. This project is part of our investment of more than DKK 80 billion in new active pharmaceutical ingredient facilities.
Key figures
5
countries with
R&D facilities
R&D facilities
290,403
DKK million in net sales
128,339
DKK million in operating profit
80
countries with
affiliates
affiliates
45.2
million people living with diabetes and obesity reached
77,349
employees worldwide
-14,707
DKK million in free cash flow
13
countries with
production facilities
production facilities
Letter from the Chair and the CEO
Chair of the Board of Directors, Helge Lund (left) and President and CEO, Lars Fruergaard Jørgensen (right).
2024 was a year of significant growth for Novo Nordisk, characterised by continued innovation, capacity expansions and strong commercial execution. As we reflect on our progress, we also recognise the magnitude of the challenges that lie ahead.
Helge Lund
Chair of the Board of Directors
Lars Fruergaard Jørgensen
President and CEO
Value creation
We focus on creating lasting value for society and our business with a strong commitment to financial, environmental and social responsibility. Following the Novo Nordisk Way, we are dedicated to delivering long-term value for people living with serious chronic diseases, our employees, partners, shareholders and society at large.